Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
This means it is being studied in clinical trials and has not yet been approved for routine medical use
The math could not be simpler
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
Collectively, estimates have suggested that the impact on cardiology services will lead to a large number of excess deaths as an indirect consequence of Covid-19.[76] It is hoped that access has subsequently improved, but some issues may still remain and could re-emerge in the event of new waves of large-scale hospitalizations
US$ 23.09
US$ 28.33
US$ 28.53
